Update on anti-tumor necrosis factor agents in Crohn disease

Siddharth Singh; Darrell S Pardi

doi:10.1016/j.gtc.2014.05.008

Update on anti-tumor necrosis factor agents in Crohn disease

Gastroenterol Clin North Am. 2014 Sep;43(3):457-78. doi: 10.1016/j.gtc.2014.05.008. Epub 2014 Jun 24.

Authors

Siddharth Singh¹, Darrell S Pardi²

Affiliations

¹ Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 200 First Street South West, Rochester, MN 55905, USA.
² Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, 200 First Street South West, Rochester, MN 55905, USA. Electronic address: Pardi.Darrell@mayo.edu.

PMID: 25110253
DOI: 10.1016/j.gtc.2014.05.008

Abstract

Anti-tumor necrosis factor-α (TNF) agents, including infliximab, adalimumab, and certolizumab pegol, are effective medications for the management of moderate to severe Crohn disease (CD). They are effective in inducing and maintaining clinical remission, inducing mucosal healing, improving quality of life, and reducing the risk of hospitalization and surgery in adult and pediatric patients with CD. Future research into comparative effectiveness of different agents, as well as better understanding of predictors of response, is warranted to allow optimization of therapeutic response.

Keywords: Adalimumab; Anti-tumor necrosis factor; Certolizumab pegol; Crohn disease; Infliximab.

Publication types

Review

MeSH terms

Adalimumab
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Certolizumab Pegol
Crohn Disease / drug therapy*
Crohn Disease / surgery
Drug Substitution
Hospitalization
Humans
Immunoglobulin Fab Fragments / therapeutic use
Infliximab
Intestinal Mucosa / drug effects
Polyethylene Glycols / therapeutic use
Quality of Life
Treatment Failure
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Wound Healing / drug effects

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Immunoglobulin Fab Fragments
Tumor Necrosis Factor-alpha
Polyethylene Glycols
Infliximab
Adalimumab
Certolizumab Pegol